A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary
about
ARID1A mutations in endometriosis-associated ovarian carcinomasClear cell carcinoma of the ovary: molecular insights and future therapeutic perspectivesAn Immunohistochemical Algorithm for Ovarian Carcinoma Typing.Type-specific cell line models for type-specific ovarian cancer researchDiagnostic utility of PAX8 in differentiation of mullerian from non-mullerian tumors.Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma.HNF-1β in ovarian carcinomas with serous and clear cell change.Calculator for ovarian carcinoma subtype prediction.Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomasNapsin A as a marker of clear cell ovarian carcinoma.Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer.Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer.Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis.Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cellsNiche-dependent gene expression profile of intratumoral heterogeneous ovarian cancer stem cell populations.Epigenetic determinants of ovarian clear cell carcinoma biology.Differences in Clinical and Biological Features Between Type I and Type II Tumors in FIGO Stages I-II Epithelial Ovarian Carcinoma.Rethinking ovarian cancer: recommendations for improving outcomes.Long-term primary culture of a clear cell ovarian carcinoma reveals an epithelial-mesenchymal cooperative interaction.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.New perspectives on molecular targeted therapy in ovarian clear cell carcinoma.DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches.Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.Clear cell adenocarcinoma of the renal pelvis in a male patient.Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features.Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum).Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.High-grade endometrial carcinomas - strategies for typing.Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review.Clear cell carcinoma of ovary and uterus.Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.High-grade serous carcinoma of tubo-ovarian origin: recent developments.Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research.Expression of angiogenic chemokines in ovarian clear cell carcinoma.Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients.Dual use of a single Wilms' tumor 1 immunohistochemistry in evaluation of ovarian tumors: a preliminary study of 20 cases
P2860
Q24610484-C7465F40-B37D-4EFF-B0A3-2BBE6D51DDD0Q26749280-F03B47DD-9CAE-4C2C-A986-1EBBF5D6B8D9Q27313766-BF4B5CD0-A7D4-488E-AEA4-E28D405C0D7EQ28536689-DE73543E-F97E-4A26-853C-081D9DA54809Q33555668-FBEC1492-E61C-4163-9531-21170A517675Q33580777-F4BA4D18-707E-47DB-A10E-B3983A5C340AQ33647555-5F45E037-9934-487A-8C4F-C6CB01791C70Q33763357-118650A1-5F76-447F-A71B-351D15A605B7Q33778612-94BBB32D-44EA-4EE7-9A4D-CF7AD2816A54Q33837822-9D762B95-502D-4148-B429-F91F91C0D73DQ34493304-7F9A4308-7322-4716-B649-4704D288ED75Q34528553-B4FB2E5F-8E00-4C86-8E09-785C0727A561Q34658626-7E5290E4-C5C2-42AB-950F-1CB70DD3ED71Q34887528-90401823-77C7-4AD0-8AB8-5F67DDF077AEQ34990141-F02D5521-4D90-41D8-8D76-944807170A77Q35051543-7BC83436-3151-45D4-A7B2-0FAE2CCC6236Q35073159-3907A8B2-B4CD-4463-86B2-19874C1E3195Q35908353-2FE856E5-BF7F-4D32-9AC7-F19C42DA3D05Q35996897-5C243F64-AC5F-404D-A923-A04E28D419C1Q36050883-36F3A8DC-3924-4206-B5A8-8A42E9841B98Q36088162-7E663372-7C3F-4007-BBD8-6E8D944A1360Q36372293-1D2C5F5B-997F-407A-BD8D-CFCED7988E22Q36889642-6B54EA8D-8347-46C8-98B0-91725B8652A0Q36889676-265B14F6-2B79-435C-962D-CE3790F4974AQ37155964-636AF163-B139-4F7B-A244-6B2CB525FA29Q37328373-86FC8FDE-AF2D-48CC-9107-65EEB759A935Q37450178-DE30D1C7-6028-4DCB-8A95-C173E5F9FD33Q37982940-80458C04-B2C2-425B-A24E-F79DA7F4D24FQ37988903-03EFAFDF-A379-4A17-B35E-21DB0DC34C50Q38067436-9ACEC493-EF13-493A-81FA-8B5C4E5A2B3DQ38067439-66652C43-1BDD-4301-9428-981474872113Q38137231-16301417-2A3C-4781-95A5-756BC7991CAAQ38151508-3D4E217B-692E-4488-94DE-025D0589A5EBQ38208388-C26D1C0C-B13C-4AE2-9660-195602BB41AAQ38687061-06C4C82C-755B-425B-A4DD-214D834699FFQ39314843-06BD605F-15F1-41FB-A7CC-94E787E3BF87Q39577538-E0B083BD-67D6-497C-821C-EA5B1E75531BQ40443875-FA3DDA9B-4623-418E-B6B0-B0B34C7944B3Q41135676-6A9D5841-6F48-41E4-8D4C-1CA9A2098F49Q41900482-B0510E1B-BF29-40CB-996E-3EF4172D25BC
P2860
A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A limited panel of immunomarke ...... serous carcinoma of the ovary
@ast
A limited panel of immunomarke ...... serous carcinoma of the ovary
@en
A limited panel of immunomarke ...... serous carcinoma of the ovary
@nl
type
label
A limited panel of immunomarke ...... serous carcinoma of the ovary
@ast
A limited panel of immunomarke ...... serous carcinoma of the ovary
@en
A limited panel of immunomarke ...... serous carcinoma of the ovary
@nl
prefLabel
A limited panel of immunomarke ...... serous carcinoma of the ovary
@ast
A limited panel of immunomarke ...... serous carcinoma of the ovary
@en
A limited panel of immunomarke ...... serous carcinoma of the ovary
@nl
P2093
P3181
P1476
A limited panel of immunomarke ...... serous carcinoma of the ovary
@en
P2093
C Blake Gilks
Carol A Ewanowich
David Huntsman
Esther Oliva
Haider Asad
Jon Carrick
Steve E Kalloger
P356
10.1097/PAS.0B013E3181788546
P407
P577
2009-01-01T00:00:00Z